Dylan Tully Selected Research

Anthracyclines

1/2019

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dylan Tully Research Topics

Disease

2	Breast Neoplasms (Breast Cancer) 01/2019 - 03/2015
2	Neoplasms (Cancer) 01/2019 - 03/2015
1	Triple Negative Breast Neoplasms 01/2019

Drug/Important Bio-Agent (IBA)

1	taxaneIBA 01/2019
1	AnthracyclinesIBA 01/2019
1	Everolimus FDA Link 01/2019
1	eribulin FDA Link 01/2019
1	Mechanistic Target of Rapamycin Complex 1IBA 03/2015
1	baicaleinIBA 03/2015
1	PlatinumIBA 03/2015

Therapy/Procedure

1	Therapeutics 01/2019
1	Drug Therapy (Chemotherapy) 03/2015
1	Chemoprevention 03/2015